Celanese Announces Emulsions Price Increases in Europe

DALLAS--(BUSINESS WIRE)-- Celanese Corporation (NYSE: CE), a global specialty materials company, today announced it will increase the price of vinyl acetate-based and styrene acrylate emulsions sold in Europe. The price increases below are for orders shipped on or after October 1, 2018, or as contracts otherwise allow. Customers are encouraged to contact their account manager for additional information.

About Celanese

Celanese Corporation is a global technology leader in the production of differentiated chemistry solutions and specialty materials used in most major industries and consumer applications. Our businesses use the full breadth of Celanese's global chemistry, technology and commercial expertise to create value for our customers, employees, shareholders and the corporation. As we partner with our customers to solve their most critical business needs, we strive to make a positive impact on our communities and the world through The Celanese Foundation. Based in Dallas, Celanese employs approximately 7,700 employees worldwide and had 2017 net sales of $6.1 billion. For more information about Celanese Corporation and its product offerings, visit www.celanese.com or our blog at www.celaneseblog.com.

All registered trademarks are owned by Celanese International Corporation or its affiliates.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180913005629/en/

Celanese Corporation
Investor Relations
Surabhi Varshney, +1-972-443-3078
[email protected]
or
Media Relations – Global
W. Travis Jacobsen, +1-972-443-3750
[email protected]
or
Media Relations Asia (Shanghai)
Helen Zhang, +86 21 3861 9279
[email protected]
or
Media Relations Europe (Germany)
Jens Kurth, +49(0)69 45009 1574
[email protected]

Source: Celanese Corporation

You May Also Be Interested In

• Celanese to sell 19% Nutrinova stake to Mitsui for $152 million
• 10 Years of the Elbphilharmonie Hamburg: Spectacular Concert Hall Celebrates Its Success Story
• Resalis Therapeutics Appoints Diana M. Røpcke as Chief Medical Officer